Findings

What do systematic reviews say?

1 questions · 3 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 33.3%Moderate 2 · 66.7%High 0 · 0%

Diarrhoea · All patients with a diagnosis of multiple myeloma

Bortezomib may leads to higher adverse Events: Diarrhoea compared with no bortezomib (low certainty).

3 findings from 1 review

Bortezomib for the treatment of multiple myeloma 2016 · Cochrane Headline outcomes only
OR 2.44 [1.74, 3.43]
8 studies · 3788 participants
Low
Bortezomib for the treatment of multiple myeloma 2016 · Cochrane Headline outcomes only
OR 6.24 [2.79, 13.98]
4 studies · 1670 participants
Moderate
Bortezomib for the treatment of multiple myeloma 2016 · Cochrane Headline outcomes only
OR 1.8 [1.22, 2.65]
4 studies · 2118 participants
Moderate